



# Dermatomyositis (DM) Clinical Trials

Principle Investigator: Victoria Werth

DM Subtype

Classic DM

With or without muscle involvement

Current drug trials

Phase 3 RCT:  
**Brepocitinib** (TYK2/JAK1 inhibitor)

Phase 3 RCT:  
**Subcutaneous IG**

Randomization design

1:1:1  
Placebo vs. 15 mg vs. 30 mg  
PO daily  
Placebo crossover at 52 weeks

1:1  
Placebo vs. IG  
SC injection weekly at home  
Placebo crossover at 24 weeks

Inclusion criteria

DM diagnosis per 2017 ACR/EULAR  
CDASI  $\geq 6$  *and*  
MMT-8 of 80-142

Probable IIM with DM rash  
CDASI  $\geq 14$  *or*  
MMT-8  $\leq 142$

Exclusion criteria

Cancer associated DM  
Hx or risk of thromboembolic events  
End stage organ involvement  
Treatment naïve

Cancer associated myositis  
Hx or risk of thromboembolic events  
Rapidly progressive ILD

If your patient may be eligible, email [penndermautoimmune@penmedicine.upenn.edu](mailto:penndermautoimmune@penmedicine.upenn.edu) for a screening appointment with Dr. Werth